DURECT News

Check below for free stories on AMAP;BT;DAR;MCP;GPS;NVDA;PTIE;DRRX;PFE;DNDN the last two weeks.

Following the market opening Friday, the Dow traded up 0.13 percent to 15,102.64, while the NASDAQ gained 0.42 percent to reach 3,423.62. The S&P also rose, increasing 0.20 percent to 1,629.90. Top Headline Gold futures saw a sharp decline on Friday, on the back of the extended rally of the US dollar against the Japanese Yen.

Pfizer's disclosure is as follows: "In 2005, King Pharmaceuticals, Inc. entered into an agreement with Pain Therapeutics, Inc.

The analysts wrote, "Durect Corporation has been downgraded by TheStreet Ratings from hold to sell.

Investors are well aware that the single biggest catalyst for shares of Durect remains the filing of the Remoxy NDA by Pfizer .

Hi good afternoon and welcome to the first quarter earnings call. This Matt Hogan, Chief Financial Officer at DURECT.

On April 30, 2013, shares of Pain Therapeutics Inc. rose over 25% after Pfizer Inc .

About DURECT Corporation DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXYA , POSIDUR, ELADURA , and TRANSDURA -Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and ... (more)